A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men.
Levels of a 90-kDa protein (90K), recently reported as a possible marker of HIV-1 infection, were serially examined in a group of HIV-1-infected (HIV-1+) and uninfected (HIV-1-) subjects drawn from the same cohort of homosexual men. The first phase of the study included 61 HIV-1+ AIDS-free subjects 4 years (+/- 6 months) postseroconversion and 75 contemporaneous unifected subjects. Two years later, a subset of 35 HIV-1+ AIDS-free subjects and 72 HIV-1- controls was examined. Mean 90K levels for HIV-1+ subjects were significantly higher than for contemporaneous HIV-1- subjects both 4 and 6 years postseroconversion (p < 0.0001). A significantly more rapid progression to AIDS was seen in HIV-1+ subjects with high 90K levels both 4 years (p = 0.01) and 6 years (p = 0.003) postseroconversion. Four years postseroconversion, 90K was significantly correlated with CD8 cell percent, interferon, neopterin, and beta 2-microglobulin (p < 0.05). Two years later, significant correlations were seen between 90K levels and CD4 cell percent, CD4 cell number, and beta 2-microglobulin (p < 0.05). Stepwise-stepdown regression modeling using 90K, CD4 cell percent, interferon, and beta 2-microglobulin levels 4 years postseroconversion showed that the predictive value of a trivariate model of 90K-interferon-CD4 percent was better than any univariate or bivariate model. We conclude that the 90K protein may be a useful predictor of progression to AIDS in HIV-1+ patients, particularly in combination with the established markers of CD4 cell percent and interferon.
Briggs
N C
NC
AIDS and Cancer Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Natoli
C
C
Tinari
N
N
D'Egidio
M
M
Goedert
J J
JJ
Iacobelli
S
S
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000453:epidemiology*; D000951:Antigens, Neoplasm; D015415:Biomarkers; D014408:Biomarkers, Tumor; D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D016516:CD4-CD8 Ratio; D002352:Carrier Proteins; D015331:Cohort Studies; D006023:Glycoproteins; D015658:HIV Infections / Q000097:blood*; D015497:HIV-1; D006716:Homosexuality; D006801:Humans; D007372:Interferons / Q000097:blood; D015993:Life Tables; D016013:Likelihood Functions; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood*; D019798:Neopterin; D011379:Prognosis; D016016:Proportional Hazards Models; D012044:Regression Analysis; D001613:beta 2-Microglobulin / Q000032:analysis; D016326:Extracellular Matrix Proteins
D000951:Antigens, Neoplasm; D015415:Biomarkers; D014408:Biomarkers, Tumor; D001708:Biopterins; D002352:Carrier Proteins; D006023:Glycoproteins; D007372:Interferons; D008074:Lipoproteins; D009363:Neoplasm Proteins; D019798:Neopterin; D001613:beta 2-Microglobulin; C081856:LGALS3BP protein, human; D016326:Extracellular Matrix Proteins